Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) is a science-driven, patient-focused company leveraging its strengths across the continuum from drug discovery to commercialization to provide better treatments for people with serious diseases.
Achillion’s rational, iterative approach to discovery and development has created a powerful engine for advancing novel small-molecule drugs. Achillion pairs this rigorous science with insights about patients, caregivers, and the healthcare market to choose product candidates with disruptive potential — or the potential to change treatment paradigms. This has already enabled Achillion to generate three clinical-stage oral chronic hepatitis C (HCV) candidates and a proprietary library of over 1,000 potent and specific complement inhibitors.
